Oxford BioDynamics (LON:OBD) Stock Price Up 12.7% – Here’s Why

Shares of Oxford BioDynamics Plc (LON:OBD) shot up 12.7% during trading on Thursday . The stock traded as high as GBX 0.31 and last traded at GBX 0.31. 28,839,465 shares changed hands during mid-day trading, an increase of 8% from the average session volume of 26,701,740 shares. The stock had previously closed at GBX 0.28.

Oxford BioDynamics Trading Down 3.2%

The company has a current ratio of 0.68, a quick ratio of 2.80 and a debt-to-equity ratio of 370.22. The company has a market cap of £12.87 million, a PE ratio of -0.38 and a beta of 0.42. The business has a 50 day simple moving average of GBX 0.26 and a two-hundred day simple moving average of GBX 0.37.

Oxford BioDynamics (LON:OBD) last announced its earnings results on Wednesday, December 24th. The biotechnology company reported GBX (0.80) earnings per share for the quarter. Oxford BioDynamics had a negative net margin of 1,800.32% and a negative return on equity of 289.38%.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.